Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: A pooled analysis of clinical studies

Current Medical Research and Opinion

Volumn 30, Issue 6, 2014, Pages 1109-1119

  Nyirjesy, Paul ^a   Sobel, Jack D ^b   Fung, Albert ^c   Mayer, Cristiana ^c   Capuano, George ^c   Ways, Kirk ^c   Usiskin, Keith ^c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Canagliflozin; Genital mycotic infection; Sodium glucose co transporter 2 (SGLT2) inhibitor; Type 2 diabetes mellitus

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CANAGLIFLOZIN; GLIMEPIRIDE; METFORMIN; METFORMIN PLUS PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSIDE; THIOPHENE DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; BALANITIS; BALANOPOSTHITIS; CIRCUMCISION; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE DURATION; DOSE RESPONSE; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; FEMALE; FEMALE GENITAL PRURITUS; FUNGAL GENITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); SEX DIFFERENCE; TIME TO TREATMENT; TOPICAL TREATMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VAGINA CANDIDIASIS; VAGINAL PRURITUS; VAGINITIS; VULVA PRURITUS; VULVITIS; VULVOVAGINITIS; AGED; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; GENITAL SYSTEM DISEASE; GYNECOLOGIC DISEASE; INCIDENCE; MICROBIOLOGY; MIDDLE AGED; MYCOSIS; RANDOMIZED CONTROLLED TRIAL;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GENITAL DISEASES, FEMALE; GENITAL DISEASES, MALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; MYCOSES; THIOPHENES;

EID: 84900823374     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.890925     Document Type: Article

References (28)

1. Grigoriou O, Baka S, Makrakis E, et al. Prevalence of clinical vaginal candid-iasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol 2006;126:121-5
2. Lisboa C, Santos A, Dias C, et al. Candida balanitis: risk factors. J Eur Acad Dermatol Venereol 2010;24:820-6
3. Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad Med 2013;125:33-46
4. Hirji I, Andersson SW, Guo Z, et al. Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database. J Diabetes Complications 2012;26:501-5
5. Goswami R, Dadhwal V, Tejaswi S, et al. Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. J Infect 2000;41:162-6
6. Polidori D, Sha S, Ghosh A, et al. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013;98:E867-71
7. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagli-flozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-8
8. Stenlöf K, Cefalu WT, Kim K-A, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82
9. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate gly-cemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care 2013;36:2508-15
10. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013;15:463-73
11. Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013;41:72-84
12. Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382:941-50
13. Lavalle-Gonzalez F, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013;56:2582-92
14. Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagli-flozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013;67:1267-82
15. Nyirjesy P, Zhao Y, Ways K, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012;28:1173-8
16. Summary of Product Characteristics. Forxiga 5 mg and 10 mg film-coated tablets. Middlesex, UK: Bristol-Myers Squibb/AstraZeneca EEIG, 2012
17. Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:479-84
18. Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metfor-min in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2013;16:147-58
19. Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013;15:1154-60
20. Haring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013;36:3396-404
21. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the canagliflozin cardiovascular assessment study (CANVAS)-A randomized placebo-controlled trial. Am Heart J 2013;166:217-23
22. Mallon E, Hawkins D, Dinneen M, et al. Circumcision and genital dermatoses. Arch Dermatol 2000;136:350-4
23. Fidel Jr PL. History and new insights into host defense against vaginal can-didiasis. Trends Microbiol 2004;12:220-7
24. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13:669-72
25. Liang Y, Arakawa K, Ueta K, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS ONE 2012;7:e30555
26. Polidori D, Sakai M, Devineni D. Exposure-response modeling of canagliflozin effects on the renal glucose threshold in subjects with type 2 diabetes (T2DM) [abstract]. Diabetes 2011;60(suppl 1):A294
27. Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab 2013;15:1136-45
28. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012;14:539-45